Amazon Enters GLP-1 Market, Pressuring Hims & Hers Health

Hims & Hers Health (HIMS) saw its shares fall 4.03% to close at $29.76 on Tuesday, reacting to the announcement that Amazon is launching its own GLP-1 weight-loss program. The decline occurred during a session where the S&P 500 fell 0.63% to 7,064 and the Nasdaq Composite slipped 0.59% to 24,260. The pullback follows a period of intense growth for the telehealth platform, which had surged 39.33% over the past week. This rally was previously driven by optimism regarding potential shifts in FDA peptide policies and a legal resolution with Novo Nordisk that ended a dispute over weight-loss medications. Trading volume for HIMS spiked to 56.7 million shares, significantly exceeding its three-month average of 37.8 million. The broader virtual care sector also faced sentiment pressures, with Teladoc Health (TDOC) falling 1.64% to $6.00 and American Well (AMWL) dropping 4.54% to $6.31. Market analysts suggest that Amazon One Medical's entry into the anti-obesity space could erode the advantages HIMS gained from its recent agreements. Specifically, Amazon's superior logistics and same-day delivery capabilities pose a direct threat to HIMS's subscriber growth and revenue streams. Investors are now shifting their focus to Hims & Hers' upcoming Q1 earnings report on May 11 to assess the actual impact of Amazon's competition on its user base and financial performance.